These results suggest that the upregulation of key survival proteins may be another mechanism by which CXCL12–CXCR4 signalling axis protects the pancreatic cancer cells from gemcitabine-induced apoptotic cell death. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.